p27-Targeted Therapeutic
Drug-resistant metastatic breast cancer
PreclinicalLead optimization & preclinical development
Key Facts
Indication
Drug-resistant metastatic breast cancer
Phase
Preclinical
Status
Lead optimization & preclinical development
Company
About Concarlo Therapeutics
Concarlo Therapeutics is pioneering a transformative approach to drug-resistant cancers by directly targeting the p27 protein, a master regulator of cell proliferation. Founded by Dr. Stacy Blain, a world expert in p27 biology, the company leverages a deep understanding of the cell cycle to develop therapies that inhibit both CDK4/6-driven proliferation and CDK2-driven resistance. With a seasoned leadership team and a clear focus on high-unmet-need oncology indications, Concarlo is positioned to address a critical gap in precision oncology where resistance remains a major challenge.
View full company profile